NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $1.75 +0.00 (+0.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.76 +0.00 (+0.11%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Iovance Biotherapeutics Stock (NASDAQ:IOVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IOVA alerts:Sign Up Key Stats Today's Range$1.73▼$1.7850-Day Range$1.66▼$3.6152-Week Range$1.64▼$12.51Volume4.64 million shsAverage Volume9.02 million shsMarket Capitalization$585.71 millionP/E RatioN/ADividend YieldN/APrice Target$12.22Consensus RatingModerate Buy Company Overview Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. Read More Iovance Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreIOVA MarketRank™: Iovance Biotherapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 208th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIovance Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Iovance Biotherapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.50% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 5.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.12 Percentage of Shares Shorted33.50% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 5.33%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.08 News SentimentIovance Biotherapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Iovance Biotherapeutics this week, compared to 12 articles on an average week.Search InterestOnly 33 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -5% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,744.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.30% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Stock News Headlines3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (IOVA)Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value...June 29, 2025 | marketbeat.comIOVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action -...July 4 at 2:12 PM | markets.businessinsider.comCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 4 at 2:00 AM | Crypto Swap Profits (Ad)Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. ...July 3 at 5:13 PM | gurufocus.comLevi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 – IOVAJuly 3 at 4:32 PM | globenewswire.comIOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 3 at 4:00 PM | globenewswire.comThe Gross Law Firm Reminds Iovance Biotherapeutics, Inc. ...July 3 at 10:15 AM | gurufocus.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVAJuly 3 at 10:00 AM | globenewswire.comSee More Headlines IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $7.40 at the beginning of 2025. Since then, IOVA shares have decreased by 76.3% and is now trading at $1.7540. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Thursday, May, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.11. The business's revenue for the quarter was up 6795.1% on a year-over-year basis. Read the conference call transcript. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings5/08/2025Today7/04/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOVA CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees500Year Founded2013Price Target and Rating Average Stock Price Target$12.22 High Stock Price Target$25.00 Low Stock Price Target$2.00 Potential Upside/Downside+596.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$372.18 million Net Margins-176.49% Pretax Margin-178.02% Return on Equity-49.71% Return on Assets-39.18% Debt Debt-to-Equity RatioN/A Current Ratio4.18 Quick Ratio3.64 Sales & Book Value Annual Sales$164.07 million Price / Sales3.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.33 per share Price / Book0.75Miscellaneous Outstanding Shares333,930,000Free Float299,539,000Market Cap$585.71 million OptionableOptionable Beta0.85 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:IOVA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.